Tests metformin for fertility in women treated with radioactive iodine for thyroid cancer
Tests metformin in women aged 18 to 45 treated with radioactive iodine for thyroid cancer.
Plain-language title generated from the registry record
Registry title: Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
Key facts
- Where
- Bialystok and Kielce, PolandSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT05468554, who can take part
Where in Poland
- Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of BialystokBialystok, PolandTaking people
- Holy Cross Cancer CenterKielce, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Bialystok
- Trial code
- NCT05468554
- Record updated
- 21 October 2026
- Original description
This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancerRead full original descriptionShow less
Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer
Inclusion: Female subjects in reproductive age >18 <45 years; Subjects with diagnosed papillary thyroid carcinoma with various pathological stage TNM (I-II); Subjects not treated with 131I; Willingness to comply with protocol procedures.
Exclusion: Hypersensitivity to metformin; Subjects with polycystic ovarian syndrome or other diseases of the ovaries (primary / secondary ovarian failure); Subjects with lactic acidosis or having history of metabolic acidosis; Subjects with history of congestive heart disease NYHA stage III/IV; Subjects with acute myocardial ischemia (CCS 3-4); Subjects with history of sepsis or severe infection; Subject with lung disease (uncontrolled asthma based on GINA 2000 Guidelines and COPD GOLD ≥ 3 stage); Alcohol or other substance dependent syndromes; Accompanying diseases with poor prognosis in the opinion of the researcher; As per Investigator (or his designee) judgement, subject cannot participate in the study due to reasons (i.e. medical, psychiatric and/or social reason); Subjects with liver malfunction and abnormal hepatitis marker results (ALT and AST activity >3ULN.*; Subjects with eGFR below 45ml/min/1.73m2.*; Subjects with serum AMH concentration* below lower range norm; Unreliability or lack of cooperation. *based on the laboratory results from screening visit; Subjects taking metformin during last week; Positive result of pregnancy test or pregnancy planned during the study; BMI <18.5 kg/m2.